Halo Therapeutics

We Develop Pan Coronavirus Antivirals

There is no home therapeutic treatment for COVID-19 patients, and similarly no prophylactic treatment for at risk patients (elderly, disease preconditions, track and trace “proximity positive” individuals, family members of positive cases).
Our vision is to solve this urgent unmet medical need by providing safe pan coronavirus antivirals which can be applied by COVID-19 patients by themselves, at home

HALO'S PROPRIETARY FREE FATTY ACID FORMULA IS A PAN CORONAVIRUS ANTIVIRAL

We recently published in Science Magazine the SARS-CoV-2 spike protein is driven to non-infectious, locked conformation by nanomolar concentrations of free fatty acid.

The pocket and antiviral mechanism we discovered are fully conserved in:

OUR PIPELINE & SCIENCE

Led by scientists with an elite level track record in drug discovery, we are advancing a pipeline of novel and proprietary pan coronavirus antiviral therapeutics by applying our expertise in structural biology, virology, and computational chemistry.

Pipeline Development Programs

Halo Antiviral Pipeline: Overview & Current Focus

INVESTMENT, LICENSING, AND PARTNERING

Please contact us for partnering, licensing, or investment opportunities in pan coronavirus antivirals and potential antiviral drugs for Covid-19.

Our Company

Halo Therapeutics develops pan-coronavirus antivirals. Founded in December 2020 and based in Bristol, UK, our vision is to roll out a class of small molecule pan-coronavirus therapeutics targeting the central axis of disease pathology: lipid regulation.

Halo Executive Team

Dr Dan Fitzgerald CEO

Dr Dan Fitzgerald CEO

  • Biotech Entrepreneur
  • Company Building
  • IP, Deal making, licencing
Prof Imre Berger CSO

Prof Imre Berger CSO

  • Wellcome Trust Investigator
  • Director, Max Planck Bristol
  • Director, EPSRC BrisSynBio
  • Serial Entrepreneur
Prof Christiane Schaffitzel CTO

Prof Christiane Schaffitzel CTO

  • Wellcome Trust Investigator
  • Discovered the Pocket
  • Cryo-EM Specialist
Dr Peter Pack NED

Dr Peter Pack NED

  • Serial Biotech CEO
  • Former Venture Capitalist
  • 29 years company building
  • Ex CEO Crescendo, Cambridge UK
  • Advises investors and biotechs
Dr. Daniel Fitzgerald

Dr. Daniel Fitzgerald

Co-Founder and CEO
  • Biotechnologist and Entrepreneur
  • Cofounded 3 startups
  • Dealmaking, company building, in/out licensing, IP
Prof. Christiane Schaffitzel

Prof. Christiane Schaffitzel

Co-Founder and CTO
  • Discovered Linoleic Acid Binding
  • Professor of Biochemistry
  • Cryo-EM Specialist
Charles Grimsdale

Charles Grimsdale

Non-Executive Director
  • Serial Entrepreneur
  • Super-Angel Investor
  • Startup Building
Prof. Imre Berger

Prof. Imre Berger

Co-Founder and CSO
  • Director, Max Planck Bristol Centre
  • Director, Bristol Synthetic Biology Centre
  • Wellcome Trust Investigator, ERC Investigator
  • Discovered Linoleic Acid COVID-19 interaction
Prof. Chris Jones

Prof. Chris Jones

Non-Executive Director
  • Former Global Head Astra Pharmaceutical Development
  • Led numerous drugs from bench to bedside
  • Developed Symbicort and Pulmicort in respiratory
Prof. Adam Finn MD PhD

Prof. Adam Finn MD PhD

  • Head clinician UK COVID-19 RECOVERY trial
  • Designing our Clinical Trials
  • Expert in viral transmission
  • COVID Key Opinion Leader
Dr. Catherine Hyams MBBS PhD

Dr. Catherine Hyams MBBS PhD

  • Respiratory clinical specialist
  • Extensive experience managing complex respiratory infection conditions.
Tony Fox MD PhD CMO

Tony Fox MD PhD CMO

  • Pharmaceutical physician 30+ years experience.
  • Former Glaxo Inc and President of EBD Group.
Prof. Adam Finn

Prof. Adam Finn

MD PhD
Dr. Catherine Hyams

Dr. Catherine Hyams

MBBS PhD
Respiratory clinical specialist with RECOVERY trial ongoing for COVID-19. Extensive experience managing complex respiratory infection conditions.
Dr. Tony Fox

Dr. Tony Fox

MD PhD

Dr. Fox is a pharmaceutical physician 30+ years experience. Former Glaxo Inc. and President of the entire EBD Group.

Tony is leading our regulatory affairs

Prof Chris Jones NED

Prof Chris Jones NED

  • Former AstraZeneca Global Head Pharma Dev
  • Developed Symbicort
  • 30+ years in big pharma
Dr. Ameet Ambarkhane, Director of Product Development

Dr. Ameet Ambarkhane, Director of Product Development

  • Multilingual in drug discovery, development and production
  • Ex Novartis, MSD
Prof. Imre Berger

Prof. Imre Berger

Co-Founder and CSO
  • Director, Max Planck Bristol Centre
  • Director, Bristol Synthetic Biology Centre
  • Wellcome Trust Investigator, ERC Investigator
  • Discovered Linoleic Acid COVID-19 interaction
Prof. Christiane Schaffitzel

Prof. Christiane Schaffitzel

Co-Founder and CTO
  • Discovered Linoleic Acid Binding
  • Professor of Biochemistry
  • Cryo-EM Specialist
Dr. Barrett Rabinow

Dr. Barrett Rabinow

PhD
Former Head Chemistry R&D at Baxter and Baxter Distinguished Scientist, 30+ years expertise in product formulation and delivery
Betty Mishkin

Betty Mishkin

Principal Medical Writer/Pharmaceutical Research Consultant Former Baxter lead on the NanoEdge™ Drug Delivery Tech Platform
Tom Pavlina

Tom Pavlina

MSc (MIT)
Former Baxter Research Scientist, 30+ years experience with lipid formulation and delivery, preclinical and clinical

NEWS

Halo Therapeutics Ltd and Oracle: Partnership against COVID

Halo Therapeutics Ltd and Oracle: Partnership against COVID

haloadmin
On 19th January 2022

Even during the strange time warp that has been the COVID-19 pandemic, opening a new calendar to a clean page headed “January” stirs the hopeful possibility of fresh starts and exciting changes.

Nurses, doctors sick. Ambulances, blood in short supply. Omicron hits L.A. healthcare hard

Nurses, doctors sick. Ambulances, blood in short supply. Omicron hits L.A. healthcare hard

haloadmin
On 14th January 2022

Registered nurse Giyun Kim, left, works with patient Marcus Miller in the COVID unit at Providence Little Company of Mary Medical Center in Torrance on Jan. 11.(Francine Orr / Los Angeles Times)

Care home residents were 18 times more likely to die than those at home

Care home residents were 18 times more likely to die than those at home

haloadmin
On 12th January 2022

New data covers the first wave of the coronavirus pandemic in England and is thought to be one of the largest analyses of care home residents.

No COVID-19 antibody response in a third of leukaemia patients

No COVID-19 antibody response in a third of leukaemia patients

haloadmin
On 8th January 2022

A third of patients with the most common type of leukaemia fail to generate any measurable antibody response following two doses of COVID-19 vaccination.

Omicron overpowers key COVID antibody treatments in early tests

Omicron overpowers key COVID antibody treatments in early tests

haloadmin
On 4th January 2022

Nearly all of the monoclonal antibodies used to prevent severe disease fail to stand up to the new variant, laboratory assays show.

Outsmarting Coronavirus: The Bristol Company Racing Against SARS-COV-2 Variants With A Pioneering Antiviral Treatment

Outsmarting Coronavirus: The Bristol Company Racing Against SARS-COV-2 Variants With A Pioneering Antiviral Treatment

haloadmin
On 22nd December 2021

A team of Bristol scientists have made an astonishing discovery; a feature of the coronavirus, and its variants, perfect for placing an antiviral molecule that could slash Covid infections.

Druggable pocket and Halo’s antiviral mechanism fully conserved in all Variants of Concern – including Omicron !

Druggable pocket and Halo’s antiviral mechanism fully conserved in all Variants of Concern – including Omicron !

haloadmin
On 11th December 2021

Druggable pocket and Halo’s antiviral mechanism fully conserved in all Variants of Concern – including Omicron !

Omicron ‘most significant threat’ of Covid pandemic, health chief warns

Omicron ‘most significant threat’ of Covid pandemic, health chief warns

haloadmin
On 11th December 2021

The omicron variant of Covid-19 is “probably the most significant threat we’ve had since the start of the pandemic” and could place

Omicron Covid wave could be worse than last winter without new lockdown, top UK scientists warn

Omicron Covid wave could be worse than last winter without new lockdown, top UK scientists warn

haloadmin
On 10th December 2021

Most pessimistic scenarios could see between 25,000 and 75,000 deaths over next five months without action

UK set for ‘rather large wave of Omicron’ and deaths, says Sage scientist

UK set for ‘rather large wave of Omicron’ and deaths, says Sage scientist

haloadmin
On 10th December 2021

Professor John Edmunds said he would be very surprised if updated vaccines to tackle variants were not needed.

UK’s progress on Covid now squandered, warns top scientist

UK’s progress on Covid now squandered, warns top scientist

haloadmin
On 2nd December 2021

Sir Jeremy Farrar, director of Wellcome Trust, suggests emergence of Omicron variant means pandemic is far from over

Covid will pose threat to UK for next five years, experts warn

Covid will pose threat to UK for next five years, experts warn

haloadmin
On 2nd December 2021

Government policy and the rate of immunity will determine how quickly coronavirus settles into a ‘predictable endemic state’, advisers say

All 17 people with suspected Omicron at superspreader Oslo Xmas party were vaccinated, officials

All 17 people with suspected Omicron at superspreader Oslo Xmas party were vaccinated, officials

haloadmin
On 2nd December 2021

At least 17 people suspected of having the Omicron variant of coronavirus after a ‘super spreader’ Christmas party in Oslo were fully vaccinated, city health officials have said.

Covid live: 75 more cases of Omicron variant found in England; Ireland announces new restrictions

Covid live: 75 more cases of Omicron variant found in England; Ireland announces new restrictions

haloadmin
On 11th November 2021

More than 100 cases of new variant have now been found in England; Strict social distancing will be required in Ireland’s bars and restaurants with mandatory table service and a maximum of six people per table.

UK Approval Of Molnupiravir May Create New And More Dangerous Covid-19 Variants

UK Approval Of Molnupiravir May Create New And More Dangerous Covid-19 Variants

haloadmin
On 8th November 2021

As of this morning, British drug regulators have approved the Covid-19 antiviral drug molnupiravir for use in Covid-19 patients at risk for severe illness, making them the first public health officials to do so.

Fatty acids could be used for antiviral treatments

Fatty acids could be used for antiviral treatments

haloadmin
On 15th June 2021

Scientists from the University of Bristol and start-up Halo Therapeutics are developing antiviral treatments that could prevent the virus from entering the body.The team recently reported a breakthrough discovery in Science magazine. They found that exposing SARS-CoV-2 to linoleic acid locks the virus’s spike protein into a closed shape. This:  blocks the virus’s entry into cells slows down its replication inside cells prevents it spreading and infecting people. The research was part-funded by the Biotechnology and Biological Sciences Council (BBSRC). A ‘pan corona’ treatment The team’s spinout company, Halo Therapeutics, was formed to take the research to clinical trials as soon as possible.Treatments under development include a nasal spray, soon to be followed by an inhaler. They work by preventing the virus penetrating cells in the:  nose throat lungs. Laboratory studies indicate that the antiviral will work against all strains, including the highly contagious Kent, South African and Brazilian variants. At home antiviral treatment Professor Imre Berger, director of the Max Planck-Bristol Centre for Minimal Biology at Bristol and Halo’s chief executive said: The aim of our treatment is to significantly reduce the amount of virus that enters the body and to stop it from multiplying. Then, even if people

An insider’s view into the battle against COVID-19 in the lab

An insider’s view into the battle against COVID-19 in the lab

haloadmin
On 27th May 2021

Taking the long view fighting COVID-19 While the world has been focused on a vaccine, Professor Imre Berger is taking the long view on coronavirus, by exploring how best to treat the virus as an ongoing problem

Forget Boris Johnson’s anti-Covid pills… scientists are now pinning their hopes on a nasal spray to reduce the severity of the disease and help stop its spread

Forget Boris Johnson’s anti-Covid pills… scientists are now pinning their hopes on a nasal spray to reduce the severity of the disease and help stop its spread

haloadmin
On 10th May 2021

It’s an attractive prospect: a single pill, popped immediately after you test positive for Covid, to stop the virus in its tracks and prevent serious disease.

Druggable pockets, the cloud, and SARS-CoV-2: An interview with Imre Berger

Druggable pockets, the cloud, and SARS-CoV-2: An interview with Imre Berger

haloadmin
On 19th April 2021

Since the novel SARS-CoV-2 coronavirus changed everyone’s lives in March 2020, an extraordinary amount of time and effort has gone into understanding and characterizing this virus.

An insider’s view into the battle against COVID-19 in the lab

An insider’s view into the battle against COVID-19 in the lab

haloadmin
On 19th April 2021

While the world has been focused on a vaccine, Professor Imre Berger is taking the long view on coronavirus, by exploring how best to treat the virus as an ongoing problem, including targeting ‘hot zones’.

BIOTECH STARTUP PIONEERS POTENTIAL TREATMENTS FOR COVID-19

BIOTECH STARTUP PIONEERS POTENTIAL TREATMENTS FOR COVID-19

haloadmin
On 16th April 2021

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing newly patented potential treatments for Coronavirus.

Bristol-based new biotech company is developing ground-breaking treatments for Covid-19

Bristol-based new biotech company is developing ground-breaking treatments for Covid-19

haloadmin
On 16th April 2021

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for Coronavirus.

Newly launched biotech company pioneers groundbreaking potential treatments for COVID-19

Newly launched biotech company pioneers groundbreaking potential treatments for COVID-19

haloadmin
On 16th April 2021

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for coronavirus.

University of Bristol Scientists Form Halo Therapeutics to Develop ‘Pan-Corona’ Antivirals

University of Bristol Scientists Form Halo Therapeutics to Develop ‘Pan-Corona’ Antivirals

haloadmin
On 16th April 2021

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for coronavirus.

Scientists Say Nasal Spray Can Prevent COVID-19 Virus From Attacking Human Cells. Find Out How.

Scientists Say Nasal Spray Can Prevent COVID-19 Virus From Attacking Human Cells. Find Out How.

haloadmin
On 14th April 2021

Based on a study of a British biotech company, they discovered a molecule that transforms the shape of the COVID-19 virus’s spike protein. The shift can prevent it from penetrating human cells.

Ground-Breaking ‘Pan-Corona Antivirals’ Could Stop SARS-CoV-2 in Its Tracks When Used at First Sign of COVID-19 Symptoms

Ground-Breaking ‘Pan-Corona Antivirals’ Could Stop SARS-CoV-2 in Its Tracks When Used at First Sign of COVID-19 Symptoms

haloadmin
On 14th April 2021

Clinical trials will shortly be launched into pivotal, cost-effective antiviral treatments for COVID-19 following the discovery of a molecule which changes the shape of the SARS-CoV-2 spike protein and in so doing inhibits the virus’ ability to enter cells.

COVID-19: Nasal spray could prevent coronavirus invading human cells

COVID-19: Nasal spray could prevent coronavirus invading human cells

haloadmin
On 13th April 2021

A British biotech company is moving towards Phase II clinical trials of a range of treatments to tackle coronavirus infections.

Newly launched British biotech pioneers ground-breaking potential treatments for COVID-19

Newly launched British biotech pioneers ground-breaking potential treatments for COVID-19

haloadmin
On 13th April 2021

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for coronavirus.

BioTech’s nasal spray ‘could stop COVID-19 in its tracks’

BioTech’s nasal spray ‘could stop COVID-19 in its tracks’

haloadmin
On 13th April 2021

A team of scientists from the University of Bristol have announced the formation of a new BioTech company developing ground-breaking and newly patented potential treatments for COVID-19.

PREV NEXT

Contact Us

For more information about Halo Therapeutics, please Contact Us and our pipeline development programs for pan coronavirus antiviral cure, get in touch with us.

Halo Therapeutics